Refine
Has Fulltext
- yes (2)
Is part of the Bibliography
- yes (2)
Document Type
- Doctoral Thesis (2) (remove)
Keywords
- diagnostics (2) (remove)
Zweck: Obwohl Bruxismus im Wesentlichen als Verhalten mit multifaktorieller Genese gilt, konnten bisher nicht eindeutig die damit assoziierten Komorbiditäten aufgeklärt werden. Die Zielsetzung war, anamnestische und psychosoziale Unterschiede zwischen Proband(inn)en mit und ohne möglichem bzw. definitivem Bruxismus zu ermitteln. Darüber hinaus sollte die Übereinstimmung verschiedener Instrumente zur Bruxismus-Diagnostik und der Effekt von zwei Interventionen (bedingte elektrische Stimulation (CES) und Kautraining) analysiert werden.
Methoden: In dieser klinischen, explorativen Studie wurden 76 Proband(inn)en untersucht. Die Proband(inn)en wurden in die drei Gruppen Kontrollgruppe, aktive Interventionsgruppe und Rehabite Interventionsgruppe eingeteilt. Die Kontrollgruppe trug ein portables EMG-Gerät (GrindCare) jede Nacht über einen Beobachtungszeitraum von 5 Wochen inaktiv. Die aktive Interventionsgruppe trug es die erste Woche inaktiv, dann 2 Wochen aktiv mit CES und anschließend erneut 2 Wochen inaktiv. Die RehaBite Interventionsgruppe verwendete das GrindCare eine Woche inaktiv, darauf folgte ein zweiwöchiges Kautraining mit einer Bissgabel namens RehaBite aber ohne EMG-Begleitung und die letzten zwei Wochen verliefen ohne Rehabite und GrindCare. Zu Beginn und am Ende des Beobachtungszeitraums füllten alle drei Gruppen die gleichen Fragebögen, u.a. die Oral Behavior Checklist (OBC) und verschiedene Fragebögen zu körperlichen und psychologischen Parametern, aus. Das GrindCare misst die Episoden und ermöglicht damit die Diagnose eines definitiven Schafbruxismus (SB).
Ergebnisse: Es existierten signifikante Unterschiede zwischen Proband(inn)en mit und ohne Bruxismus (möglicher und definitiver SB, möglicher Wachbruxismus (WB), möglicher kombinierter SB und WB) in diversen anamnestischen und psychosozialen Parametern. Außerdem bestand ein signifikanter Zusammenhang zwischen erhöhter Kieferaktivität (diagnostiziert mittels OBC) und SB- sowie WB-Selbstangabe sowie zwischen den Selbstangaben von SB und WB untereinander, nicht jedoch zwischen Fragebögen und apparativer Diagnostik. Die CES bewirkte keine Reduktion der Episoden, dafür verbesserten sich jedoch einzelne körperliche und psychosoziale Parameter in der aktiven bzw. in der Rehabite Gruppe im Laufe des Beobachtungszeitraums.
Fazit: Personen mit und ohne möglichem bzw. definitivem Bruxismus unterschieden sich in verschiedenen anamnestischen, körperlichen und psychosozialen Eigenschaften voneinander. Außerdem bestehen signifikante Korrelationen zwischen SB und WB laut Selbstangabe, nicht jedoch bezüglich der apparativen Bruxismus-Diagnostik mit dem GrindCare. Während die Episoden nicht durch die CES gesenkt wurden, verringerten sich -eventuell durch RehaBite bzw. CES bedingt- bestimmte Beschwerden. Weiterer Forschungsbedarf besteht, um auf der Basis größerer Stichproben die gefundenen Auffälligkeiten statistisch abzusichern.
Peptide receptor radionuclide therapy (PRRT) is a molecular targeted radiation therapy involving the systemic administration of radiolabeled somatostatin receptor binding peptides designed to target with high affinity and specificity receptors overexpressed on tumors. Peptides are applied which either target as agonist (with internalization) or antagonist (little to no internalization). Recently, two novel antagonistic agents have been developed for clinical use: OPS202 and OPS201. 68Ga-labelled OPS202 is used for diagnostic purposes with positron emission tomography and 177Lu-labelled OPS201 is used for the therapy in patients with neuroendocrine tumors (NETs). Both agents are presently under clinical evaluation. Despite the very low internalization rate, the use of somatostatin receptor antagonists which target more binding sites on receptors are expected to result in higher specificity, more favorable pharmacokinetics and higher tumor retention and better visualization than the agonists. The main goal of this thesis was analyzing the biodistribution, biokinetics and internal dosimetry of the recently developed somatostatin receptor antagonists (OPS201 and OPS202) for therapeutic and diagnostic purposes in different species (mice, pigs and patients). In addition, an analysis of the influence of image quantification and the integration of time activity curves on kidney dosimetry in a pig model was carried out. Furthermore, extrapolation methods, which are used for predicting organ absorbed doses for humans based on preclinical animal models, were systematically compared for blood, liver, and kidneys of OPS201 injected species. Based on the OPS202 injected patients’ investigations, 68Ga-OPS202 shows promising biodistribution and imaging properties with tumor contrast which is optimal one hour after injection of the radiotracer. OPS202 is well tolerated and delivers absorbed doses to organs that are lower than those by 18F-FDG and similar to other 68Ga-labeled somatostatin receptor ligands. As a result of 68Ga OPS202 injection, the highest absorbed doses were observed in the urinary bladder (0.10 mGy/MBq) and kidneys (0.84 mGy/MBq). The calculated mean effective dose coefficient of 68Ga-OPS202 injected patients was 0.024 mSv/MBq (3.6 mSv for 150 MBq 68Ga-OPS202 injection) which is similar to other 68Ga-labeled compounds. Based on the OPS201 biokinetics and dosimetry investigations, after the injection of 177Lu-OPS201, a fast blood clearance of the compound is observed in the first phase (half-life: 1.83 h) for each species. 10 min after injection, less than 5% of the injected activity per milliliter of blood circulates in pigs and humans. The analysis of the mice, pig and preliminary patient data provides evidence that, patients enrolled in a phase 1 177Lu-OPS201 trial would not be at risk of overexposure. Based on our results, for 177Lu labelled studies, late time points after 72 h have a great impact on absorbed dose calculations. That is why follow-up times especially at late time points (more than 72 h) are required for the time-integrated activity coefficient (TIAC) calculations in order to represent the area under the curve appropriately and to analyze both biokinetics and dosimetry accurately. In addition, to find the most adequate extrapolation methods that minimize the interspecies differences of dosimetry data, several extrapolation methods from animal to human have been tested. For OPS201 time scaling or combination of relative mass and time scaling results in most similar TIAC values, if the organ mass ratios between the species are high. In time scaling, the scan/sampling time is scaled by using the ratio of the whole body masses of the respective species. In relative mass scaling, the TIACs are scaled based on the ratio of the whole body and organ mass of respective species. Other methods tested showed higher deviations. For the study on the influence of image quantification and the choice of the optimal scanning time points, a study in a pig model, which was performed in collaboration with Aalborg University and Octreopharm Sciences GmbH, was reanalyzed. As kidneys are organs-at-risk in PRRT with 177Lu labelled peptides, several quantification methods, based on 2D and 3D quantitative imaging were chosen. For this purpose, a 3D printed pig kidney phantom was prepared and measured with/without background activities representing the activities in the pig SPECT/CT scans. The phantom dosimetry data based on multiple SPECT/CT images and based on multiple planar images in combination with one SPECT/CT scan (MP1S Imaging) were compared to the pig dosimetry. The calculated TIACs of the phantom with background based on multiple SPECT/CT and MP1S imaging were quite similar to the multiple SPECT/CT based pig TIAC. In addition, in order to investigate the effect of late time points on dosimetry and absorbed dose values in 177Lu therapies, the difference, associated with eliminating the late two scan time points, on the TIACs was analyzed. When the TIACs (including all time points) of the pig based on multiple SPECT/CT and MP1S imaging were investigated, the use of MP1S imaging results in considerably lower TIAC values to the kidney (by a factor of 1.4). With eliminating late time points from the created time activity curve, the factor increases up to 2.4 times with a corresponding increase in TIAC uncertainties. As a consequence, further evaluation of 68Ga-OPS202 for PET/CT imaging and 177Lu-OPS201 for the treatments of NET patients is necessary. In particular, a head-to-head comparison of agonists and OPS peptides with respect to biokinetics, biodistribution and dosimetry would be helpful. In addition, the influence of the late scan time points on dosimetry needs further attention in particular for kidney dosimetry